Desmopressin-Induced Severe Hyponatremia with Central Pontine Myelinolysis: A Case Report
Tóm tắt
Desmopressin, a synthetic vasopressin analog, is used to treat central diabetes insipidus, hemostatic disorders such as von Willebrand’s disease, and nocturnal enuresis. We present the case of a 69-year-old man who developed severe hyponatremia during treatment with intranasal desmopressin at 10 µg twice daily for chronic polyuria and nocturia thought to be due to central diabetes insipidus. After 5 months of therapy, the patient noticed progressive fatigue, anorexia, dizziness, weakness, light-headedness, decreased concentration, and new-onset falls. At 6 months of therapy, the patient was brought to the emergency department for altered mental status and was found to be severely hyponatremic with a serum sodium level of 96 mmol/L, down from a value of 134 mmol/L at the initiation of therapy. The intranasal desmopressin was discontinued and the patient was admitted to the intensive care unit where the hyponatremia was slowly corrected over the next week to 132 mmol/L, never increasing by more than 8 mmol/L a day, with careful fluid management. This included infusion of over 11 L of 5% dextrose to account for a high urine output, which peaked at 7.4 L in 1 day. However, while the recommended rate for sodium correction was followed, the patient’s magnetic resonance imaging of the brain obtained after discharge displayed evidence of central pontine myelinolysis. Despite this finding, the patient eventually returned to his baseline mental status with no permanent neurologic deficits.
Tài liệu tham khảo
Arima H, Oiso Y, Juul KV, Norgaard JP. Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study. Endocr J. 2013;60(9):1085–94.
Berges R, Hofner K, Gedamke M, Oelke M. Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). World J Urol. 2014;32(5):1163–70. https://doi.org/10.1007/s00345-014-1381-7.
Kayamori K, Fujitani J, Kawachi S. Efficacy of intranasal desmopressin for the treatment of nocturnal polyuria in the elderly females. Nihon Ronen Igakkai Zasshi. 2014;51(1):85–8.
Lee HW, Choo MS, Lee JG, Park CH, Paick JS, Lee JZ, et al. Desmopressin is an effective treatment for mixed nocturia with nocturnal polyuria and decreased nocturnal bladder capacity. J Korean Med Sci. 2010;25(12):1792–7. https://doi.org/10.3346/jkms.2010.25.12.1792.
Sharma R, Stein D. Hyponatremia after desmopressin (DDAVP) use in pediatric patients with bleeding disorders undergoing surgeries. J Pediatr Hematol/Oncol. 2014;36(6):e371–5. https://doi.org/10.1097/mph.0000000000000185.
Shulman LH, Miller JL, Rose LI. Desmopressin for diabetes insipidus, hemostatic disorders and enuresis. Am Fam Phys. 1990;42(4):1051–7.
Stoof SC, Cnossen MH, de Maat MP, Leebeek FW, Kruip MJ. Side effects of desmopressin in patients with bleeding disorders. Haemophilia. 2016;22(1):39–45. https://doi.org/10.1111/hae.12732.
Vande Walle J, Stockner M, Raes A, Norgaard JP. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007;2(3):232–8.
Wang CJ, Lin YN, Huang SW, Chang CH. Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study. J Urol. 2011;185(1):219–23. https://doi.org/10.1016/j.juro.2010.08.095.
Weiss JP, Zinner NR, Klein BM, Norgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012;31(4):441–7. https://doi.org/10.1002/nau.22243.
Juul KV, Bichet DG, Nielsen S, Norgaard JP. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am J Physiol Renal Physiol. 2014;306(9):F931–40. https://doi.org/10.1152/ajprenal.00604.2013.
MacKenzie JS, Kozinn SC. Peri-operative DDAVP use leading to severe hyponatremia after total shoulder replacement in a patient with von Willebrand’s disease. HSS J. 2015;11(3):281–4. https://doi.org/10.1007/s11420-015-9457-5.
Behan LA, Sherlock M, Moyles P, Renshaw O, Thompson CJ, Orr C, et al. Abnormal plasma sodium concentrations in patients treated with desmopressin for cranial diabetes insipidus: results of a long-term retrospective study. Eur J Endocrinol. 2015;172(3):243–50. https://doi.org/10.1530/eje-14-0719.
Bernstein SA, Williford SL. Intranasal desmopressin-associated hyponatremia: a case report and literature review. J Fam Pract. 1997;44(2):203–8.
Choi EY, Park JS, Kim YT, Park SY, Kim GH. The risk of hyponatremia with desmopressin use for nocturnal polyuria. Am J Nephrol. 2015;41(3):183–90. https://doi.org/10.1159/000381562.
Ebell MH, Radke T, Gardner J. A systematic review of the efficacy and safety of desmopressin for nocturia in adults. J Urol. 2014;192(3):829–35. https://doi.org/10.1016/j.juro.2014.03.095.
Guo J, Wang D, Zeng K, Xu G, Zhao Y. Generalized tonic-clonic seizures in adult patients following intravenous administration of desmopressin. Aging Clin Exp Res. 2013;25(4):479–81. https://doi.org/10.1007/s40520-013-0064-3.
Juul KV, Schroeder M, Rittig S, Norgaard JP. National Surveillance of Central Diabetes Insipidus (CDI) in Denmark: results from 5 years registration of 9309 prescriptions of desmopressin to 1285 CDI patients. J Clin Endocrinol Metab. 2014;99(6):2181–7. https://doi.org/10.1210/jc.2013-4411.
Lucchini B, Simonetti GD, Ceschi A, Lava SA, Fare PB, Bianchetti MG. Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: a systematic review. J Pediatr Urol. 2013;9(6 Pt B):1049–53.
Ooi HL, Maguire AM, Ambler GR. Desmopressin administration in children with central diabetes insipidus: a retrospective review. J Pediatr Endocrinol Metab. 2013;26(11–12):1047–52. https://doi.org/10.1515/jpem-2013-0078.
Posthouwer D, Rommes JH, Van Bemmel TJ, Schaar CG. Severe hyponatraemia after DDAVP stimulation test in an adult patient. Haemophilia. 2008;14(4):844–5. https://doi.org/10.1111/j.1365-2516.2008.01756.x.
Robson WL, Leung AK, Norgaard JP. The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol. 2007;178(1):24–30. https://doi.org/10.1016/j.juro.2007.03.015.
Robson WL, Norgaard JP, Leung AK. Hyponatremia in patients with nocturnal enuresis treated with DDAVP. Eur J Pediatr. 1996;155(11):959–62.
Song M, Hong BS, Chun JY, Han JY, Choo MS. Safety and efficacy of desmopressin for the treatment of nocturia in elderly patients: a cohort study. Intern Urol Nephrol. 2014;46(8):1495–9. https://doi.org/10.1007/s11255-014-0679-0.
Steendam CM, Vincent HH, Kastelijn EA. Neurological complications caused by desmopressin in adults with nocturia. Ned Tijdschr Geneeskd. 2011;155(29):A3273 (in Dutch).
Thumfart J, Roehr CC, Kapelari K, Querfeld U, Eggert P, Muller D. Desmopressin associated symptomatic hyponatremic hypervolemia in children: are there predictive factors? J Urol. 2005;174(1):294–8. https://doi.org/10.1097/01.ju.0000161213.54024.7f (discussion 8).
Upton TJ, Hunt PJ, Doogue MP. Hyponatraemic seizure following arginine vasopressin for von Willebrand disease: pernicious, predictable and preventable. Intern Med J. 2014;44(5):521–2. https://doi.org/10.1111/imj.12404.
Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurourol Urodyn. 2004;23(4):302–5. https://doi.org/10.1002/nau.20038.
Williford SL, Bernstein SA. Intranasal desmopressin-induced hyponatremia. Pharmacotherapy. 1996;16(1):66–74.
Yalcin A, Silay K, Yilmaz T, Atmis V, Atli T. Severe hyponatremia after desmopressin diacetate arginine vasopressin infusion in an older woman. J Am Geriatr Soc. 2016;64(5):1138–9. https://doi.org/10.1111/jgs.14094.
Achinger SG, Arieff AI, Kalantar-Zadeh K, Ayus JC. Desmopressin acetate (DDAVP)-associated hyponatremia and brain damage: a case series. Nephrol Dial Transplant. 2014;29(12):2310–5. https://doi.org/10.1093/ndt/gfu263.
Gutenstein M. Osmotic myelinolysis syndrome after treatment of severe deamino arginine vasopressin-associated hyponatraemia: pitfalls in emergency medicine. Emerg Med Australas. 2007;19(1):68–70. https://doi.org/10.1111/j.1742-6723.2007.00931.x.
Kataoka Y, Nishida S, Hirakawa A, Oiso Y, Arima H. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus. Endocr J. 2015;62(2):195–200. https://doi.org/10.1507/endocrj.EJ14-0368.
Ranger A, Szymczak A, Levin S, Salvadori M, Fraser DD. Osmotic myelinolysis with malignant cerebellar edema occurring after DDAVP-induced hyponatremia in a child. Pediatr Neurosurg. 2010;46(4):318–23. https://doi.org/10.1159/000320146.
Sterns RH, Silver SM. Complications and management of hyponatremia. Curr Opin Nephrol Hypertens. 2016;25(2):114–9. https://doi.org/10.1097/mnh.0000000000000200.